Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight

Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $28.00 (from $50.00) while maintaining a In Line rating.

The analyst comments "Following the second recent Elevidys-related death due to liver failure, were reiterating our In-Line rating and lowering our PT to $28/sh. See our previous downgrade note for more details on the broader setup. Some thoughts on the path forward: Tough to... More

Goldman Sachs Downgrades Sarepta Therapeutics (SRPT) to Neutral

Goldman Sachs analyst Salveen Richter downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Buy to Neutral with a price target of $29.00.

The analyst comments "We downgrade SRPT to Neutral from Buy as we see an uncertain outlook amidst safety concerns, following the second reported death of a non-ambulatory Elevidys-treated Duchenne muscular dystrophy patient due to acute liver failure (ALF). SRPT plans to convene a Duchenne and liver health expert panel to consider enhanced immunosuppression, as the company believes that adding... More

Sarepta Therapeutics (SRPT) call put ratio 2.1 calls to 1 put with a focus on August 60 and 70 calls as share price down 43%

Sarepta Therapeutics (NASDAQ: SRPT) 30-day option implied volatility is at 105; compared to its 52-week range of 33 to 142. Call put ratio 2.1 calls to 1 put with a focus on August 60 and 70 calls as share price down 43%.

Cantor Fitzgerald Downgrades Sarepta Therapeutics (SRPT) to Neutral

Cantor Fitzgerald analyst Kristen Kluska downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Neutral with a price target of $20.00 (from $81.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $36.18 yesterday.

BMO Capital on Sarepta (SRPT) Following Earlier Downgrade: 'we believe management could potentially turn the story around'

BMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $70.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "Management is taking all the right/necessary measures to understand the recent non-ambulatory patient deaths and prevent future ambulatory/non-ambulatory deaths. Given the significant... More

BofA Securities Downgrades Sarepta Therapeutics (SRPT) to Neutral

(Updated - June 16, 2025 10:06 AM EDT)

BofA Securities analyst Tazeen Ahmad downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Buy to Neutral with a price target of $28.00 (from $76.00).

The analyst comments "We are downgrading SRPT to Neutral from Buy with new $28 PO (prev. $76; see... More

UBS Reiterates Buy Rating on Sarepta Therapeutics (SRPT)

UBS analyst Eliana Merle reiterated a Buy rating and $85.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst commented, "We highlight we hosted a call with a former FDA reviewer Friday 6/13 (before 2nd death reported); his view is that given there had... More

Sarepta shares under pressure, analysts flag risks after second Elevidys-linked death

Investing.com -- BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ: SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular dystrophy (DMD) patient.

Shares of the company are down around 35% in... More

Sarepta Therapeutics (SRPT) Provides Safety Update for ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta extends its deepest sympathies to the affected families and care teams.

Key Safety... More

H.C. Wainwright Downgrades Sarepta Therapeutics (SRPT) to Sell

(Updated - June 16, 2025 6:35 AM EDT)

H.C. Wainwright analyst Mitchell S. Kapoor downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Neutral to Sell with a price target of $10.00.

The analyst comments "Second ELEVIDYS death leads to commercialization halt and confirmatory study pause in non-ambulatory DMD. Sarepta announced another... More

Stocks expected to have increasing option volume: SRPT CCL SATS X

Stocks expected to have increasing option volume: SRPT CCL SATS X

Sarepta Therapeutics (SRPT) 30-day option implied volatility is at 74 into share price lower before the bell

Sarepta Therapeutics (NASDAQ: SRPT) 30-day option implied volatility is at 74 compared to its 52-week range of 33 to 142 into suspends non-ambulatory Elevidys shipments after second death.

BMO Capital Downgrades Sarepta Therapeutics (SRPT) to Market Perform

BMO Capital analyst Kostas Biliouris downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform to Market Perform with a price target of $70.00 (from $120.00).

The analyst comments: "Elevidys treatment led to a second fatal case of acute liver failure in non-ambulatory patients, triggering management to look for... More

Piper Sandler Downgrades Sarepta Therapeutics (SRPT) to Neutral

Piper Sandler analyst Biren Amin downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Neutral with a price target of $36.00 (from $70.00).

The analyst comments: "Early Sunday, SRPT announced that a 2nd non-ambulatory patient has died due to acute liver failure due to Elevidys,... More